GENOMIC PREDICTORS OF CLINICAL OUTCOMES AND BENEFIT OF (CHEMO)HORMONAL THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER.
$352,846FY2020Defense Health AgencyDOD
Dana-Farber Cancer Institute, Inc.
Investigators
View source on USAspending →GENOMIC PREDICTORS OF CLINICAL OUTCOMES AND BENEFIT OF (CHEMO)HORMONAL THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER. · GrantIndex